We serve Chemical Name:3-chloroheptafluoro-2-butene CAS:434-41-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-chloroheptafluoro-2-butene
CAS.NO:434-41-3
Synonyms:MFCD00039261;2-chloro-1,1,1,3,4,4,4-heptafluorobut-2-ene;3-Chloroheptafluoro-2-butene
Molecular Formula:C4ClF7
Molecular Weight:216.48500
HS Code:2903799090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:32°C
Density:1,548 g/cm3
Index of Refraction:1.2946
PSA:
Exact Mass:215.95800
LogP:3.53090
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:I
Contact us for information like MFCD00039261 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Chloroheptafluoro-2-butene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Chloroheptafluoro-2-butene Use and application,MFCD00039261 technical grade,usp/ep/jp grade.
Related News: The incredible selectivity of enzyme catalysts consequently simplifies workflows by generating fewer by-products and reducing impurities to markedly decrease the total number of synthetic steps required. methyl 3-(4-((3-(2,6-dimethylbenzyl)benzyl)oxy)phenyl)propanoate manufacturers Moderna filed an application with the FDA for that same younger age group on June 10 but has yet to hear from the agency. States like Rhode Island have already signed off on allowing 12 to 17-year-olds to use the vaccine. 5-chloro-3-((4-chloro-N-(methoxymethyl)-3-(trifluoromethyl)phenyl)sulfonamido)-N-isopropyl-N-phenylpicolinamide suppliers In taking control of Vanamali, Wavelength will double the firm’s production capacity and add more than 10 key regulatory starting materials and drug intermediates for Wavelength’s own strategic APIs and API CDMO customers, a Wavelength spokeswoman said by email. 8-epi-caryoptoside tetraacetate vendor & factory In taking control of Vanamali, Wavelength will double the firm’s production capacity and add more than 10 key regulatory starting materials and drug intermediates for Wavelength’s own strategic APIs and API CDMO customers, a Wavelength spokeswoman said by email.,With rising demand and approvals required for new drugs, an external collaboration with CDMOs helps in driving a successful and robust clinical development plan for a new drug molecule.